Day: April 7, 2021

SOCIETE GENERALE ENTERS INTO EXCLUSIVE NEGOTIATION WITH AMUNDI WITH A VIEW TO DISPOSING OF THE ASSET MANAGEMENT ACTIVITIES OPERATED BY LYXOR Paris, 7 April 2021 Societe Generale’s Board of Directors approved, during a meeting on 6 April 2021, the entry into exclusive negotiation with Amundi with a view to disposing of the asset management activities operated by Lyxor. Lyxor is an entity which includes the Group’s asset management activities and operates in particular through Lyxor Asset Management, a wholly owned subsidiary of Societe Generale. Created in 1998, Lyxor has played a pioneering role in specialised asset management and has notably reached leadership positions in passive asset management. Lyxor’s assets under management represent approximately EUR 140 billion at the end of December 2020 of which EUR 124 billion are in...

 Press release Paris, April, 7th 2021 Amundi enters into exclusive negotiations for the acquisition of Lyxor Amundi announces that it has entered into exclusive negotiations with Société Générale for the acquisition of Lyxor1 for a total cash consideration of €825m, or €755m excluding excess capital2. Founded in 1998, Lyxor is a pioneer in ETF in Europe and has €124bn3 in Assets under Management (AuM). Lyxor is one of the key players in the ETF market (€77bn of AuM4, 3rd largest player in Europe with a 7.4% market share5) and has developed a recognized expertise in active management (€47bn of AuM), notably through its leading alternative platform6. Thanks to this acquisition, Amundi would become the European leader in ETF, with €142bn combined AuM, a 14% market share in Europe7 and a diversified profile in terms of client base and geography. Amundi...

07/04/2021 LACROIX unveils LEADERSHIP 2025, its new strategic plan Strong ambitions:Becoming an international market leader in industrial IoT solutions andelectronic equipments for critical applications Accelerating and moving up to a new dimension by 2025€800m revenue and EBITDA margin1of approximately 9% “Since 2016, our Group has embarked on an in-depth transformation that has strengthened its technological expertise and achieved solid revenue and earnings growth. Thanks to these foundations, we have been able to demonstrate our resilience in the face of the unprecedented crisis that marked 2020. We are once again ready to look ahead to the future, driven by strong ambitions that will drive our development for the next five years. This is what the Leadership 2025 plan is all about. It will enable us to build an international market...

07/04/2021 LACROIX présente LEADERSHIP 2025, son nouveau plan stratégique Des ambitions fortes :Devenir un leader international des solutions IoT industrielles etdes équipements électroniques pour les applications critiques. Accélérer et changer de dimension d’ici 2025800 M€ de chiffre d’affaires et une marge d’EBITDA1 d’environ 9%. « Depuis 2016, notre Groupe s’est engagé dans une transformation en profondeur qui lui aura notamment permis de renforcer ses expertises technologiques et de s’inscrire dans une trajectoire solide de croissance et de progression de ses résultats. Grâce à ces fondations, nous avons pu démontrer notre résilience face à la crise sans précédent qui a marqué l’année 2020. Nous sommes prêts à nous projeter à nouveau vers l’avenir, animés par des ambitions fortes qui porteront notre développement pour les cinq prochaines...

  Communiqué de presse Paris, le 7 avril 2021 Entrée en négociation exclusive en vue de l’acquisition de Lyxor par Amundi Amundi annonce être entrée en négociation exclusive avec Société Générale en vue de l’acquisition de Lyxor1 pour un prix en numéraire de 825 M€ (soit 755 M€ hors capital excédentaire)2. Fondé en 1998 et pionnier des ETF en Europe, Lyxor gère 124 Md€ d’encours3. Lyxor est l’un des acteurs majeurs sur le marché des ETF (77 Md€ d’encours4, 3e acteur en Europe avec une part de marché de 7,4%5) et dispose  d’expertises reconnues  en gestion active (47 Md€), notamment à travers sa plateforme de gestion alternative de premier plan6. Avec cette opération, Amundi deviendrait le leader européen de la gestion des ETF,  avec 142 Md€ d’encours combinés, une part de marché de 14% en Europe7, et un profil diversifié tant en terme...

Anti-p53 antibodies are antibodies that mistakenly target a patient’s own tissues, leading to a growth of solid tumors. Screening for Anti-p53 helps to diagnose throat, bowel and breast cancers earlier, thereby increasing the chances that a patient responds to a treatment The Elecsys Anti-p53 could be used to monitor cancer cell remnants in the patient’s bodyBasel, 07 April 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the Elecsys Anti-p53 immunoassay for the in vitro quantitative determination of anti-p53 antibodies. This test is used to aid physicians to diagnose throat cancer, bowel cancer and breast cancer in patients, in conjunction with other diagnostic tests. The assay is now available for all markets accepting the CE Mark. “The addition of our Elecsys Anti-p53 immunoassay will help clinicians...

Corbion has published its agenda for the upcoming Annual General Meeting of Shareholders (AGM) to be held on 19 May 2021. In view of the COVID-19 pandemic and the related measures Corbion has decided that the AGM will be a fully virtual meeting. This means that shareholders will be able to attend the AGM via webcast and may ask questions up to 72 hours prior to the AGM. For more details, please be referred to the convocation for the AGM. The full AGM agenda together with explanatory notes is available on Corbion’s website under Investor relations –> Shareholder information –> Shareholder meetings. AttachmentPress release AGM_agenda_ENG_2021

Corbion heeft de agenda gepubliceerd voor de aanstaande jaarlijkse Algemene Vergadering van Aandeelhouders (AvA), die op 19 mei 2021 wordt gehouden. In verband met de COVID-19 pandemie en de daarmee samenhangende maatregelen, heeft Corbion besloten dat het een volledig virtuele vergadering zal zijn. Dit betekent dat aandeelhouders kunnen deelnemen aan de AvA via een webcast en vragen kunnen indienen tot 72 uur voor aanvang van de AvA. Nadere details staan vermeld in de oproeping voor de AvA. De integrale AvA-agenda, inclusief toelichting bij de agendapunten, is beschikbaar op de website van Corbion onder Investor Relations –> Shareholder information –> Shareholder meetings. BijlagePress release AGM_agenda_NL_2021

Pixium Vision announces first patient successful implantation in Prima System pivotal trial PRIMAveraStudy is the last clinical step before seeking market approval in Europe in dry AMD Bionic vision Prima System has shown excellent results in improving vision              Paris, France, April 7, 2021 – 7.00 a.m. CEST – Pixium Vision SA (Euronext Growth Paris – FR0011950641), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, announces the successful first implantation of a patient in the PRIMAvera pivotal trial of its bionic vision Prima System for atrophic dry age-related macular degeneration (AMD). The PRIMAvera study was initiated in Q4 2020 and aims to confirm the safety and the benefits provided by the Prima System and is the...

According to his personal release, “The CMBS Market goes through cycles of uncertainty, and in the year plus since the COVID-19 Pandemic began, the CMBS Industry has showed true resiliency. Fitch expected the U.S. CMBS Market Delinquency rate to top out at about 8.25% to 8.75% for last year, but that prediction was high as the real number came in a 5.0%. Now of course government intervention and some debt relief play roles, but on the flip side of that coin if there was no pandemic, there would have been no crisis. Last month Fitch Ratings showed further decline in delinquencies, down to about 4.33%, and a further drop to 4% is expected here in the short-term.” “Due to our relationships with both banking and non-banking lenders, REITS, Family Offices, Hedge Funds and other Qualified Institutional Investors, the ‘race to the bottom’ for...